NCT03071055View on ClinicalTrials.gov

Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF

PHASE2CompletedINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

October 1, 2017

Primary Completion Date

June 3, 2019

Study Completion Date

June 3, 2019

Conditions

Exudative Age Related Macular Degeneration

Interventions

DRUG

Ranibizumab Injection [Lucentis]

intravitreal injection

Trial Locations (2)

28210

Charlotte Eye Ear Nose and Throat Associates, PA, Charlotte

28677

Charlotte Eye Ear Nose and Throat Associates, PA, Statesville

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

Southeast Clinical Research Associates, LLC

OTHER